Article and Video CATEGORIES

Cancer Journey

Search By

Blood Cancer Video Library - What Is The Significance Of IGHV Mutations And How Are They Assessed?
Tue, 06/21/2016 - 00:00
GRACE Videos and Articles

We recently joined a number of top faculty in the area of hematology in Whistler BC, for the 3rd Annual Summit on Hematologic Malignancies.

Jennifer Brown, MD, PhD, Director of the CLL Center at the Dana-Farber Cancer Institute spoke with GRACE and provided provoking and educational discussions on the significance of IGHV mutations and how they are assessed. We invite you to watch this first video from our Blood Cancers Library Video collection.

Stay tuned for more educational videos soon to come!


What is the significance of IGHV mutations and how are they assessed?

Jennifer Brown, MD, PhD, Director of the CLL Center at the Dana-Farber Cancer Institute


Now we are going to talk about whether there’s still a role for chemotherapy or chemoimmunotherapy in the treatment of CLL, now in the era of novel kinase inhibitors. This is a very important topic because we have some new recent exciting data on the potential benefits of chemotherapy. As you know, the standard chemoimmunotherapy treatment now for fit younger CLL patients is something called FCR (fludarabine, cyclophosphamide and rituximab) and this is a treatment given infusionally by vein for three days, every four weeks, for about six months. This treatment has been studied in multiple large trials and we now have long follow up from three of them that report specifically on a genetic subgroup of CLL, a subgroup of something called mutated IGHV, which I’ll explain more in a minute. These three trials all report that people with mutated IGHV CLL can have extremely long duration of remission after FCR treatment. In fact, at twelve years, about 60% of such people are still in remission and likely many of them are cured, many of them have no evidence of disease by the most sensitive tests. So, what does it mean to have mutated IGHV? The IGHV test is something that we do on the CLL cells. CLL cells come from a normal cell called a B-lymphocyte, and B-lymphocytes have an antibody gene in them. The antibody gene can get changed over the course of the life cycle of the B-lymphocyte. All CLL cells have the same one and it turns out that how much the antibody gene has changed from the day you were born has a very strong impact on the way CLL behaves. So, a so-called mutated IGHV shows much greater change from the way it was when you were born in the antibody gene. This has been found empirically to associate with better behaving CLL, longer time to treatment and better response to treatment, and now with these FCR studies, perhaps even cure with FCR. The other subgroup of CLL, the unmutated group, has an antibody gene in their CLL cells that looks much more similar to how the gene was when you were born which is why it’s called unmutated. It is associated with more steadily progressive disease and after FCR; we see more steady relapse although the median duration remission is still on the order of about four to five years.

Video Language

Next Previous link

Previous PostNext Post

Related Content

Mandarin LCVL
王林医生用普通话讨论重要的肺癌信息。这些信息包括靶向治疗、晚期疾病的症状、循环肿瘤 DNA、治疗方案等。我们鼓励您与社区中说普通话的人分享。 Dr. Lin Wang discusses important lung cancer information in Mandarin. This information includes targeted therapy, symptoms of advanced disease, circulating tumor DNA, treatment options, and more. We encourage you to share this with the Mandarin speakers in your community. To watch the complete Playlist visit:…;  
Tell your story!  Apply now for the Clinical Trials Experiences through Storytelling Program
We are excited to launch our third year of this program; tell your story and help us help others! Apply Online Now!     GRACE Patient Perspectives: Clinical Trials Experiences Storytelling Program Overview  
Blood Cancer OncTalk
Blood Cancer OncTalk was a live presentation that brought together top oncologists to discuss emerging concepts and treatment options in blood cancer. The program was chaired by Dr. Aaron Goodman, with the participation of Dr. Mazie Tsang, Hematologist / Oncologist; Dr. Autumn Jeong, Hematologist / Oncologist; Dr. Shaji Kumar, Hematologist / Oncologist; and Dr. Sridevi Rajeeve, Hematologist / Oncologist.

Forum Discussions

Hi Caregiver and welcome to Grace.  I'm sorry that you need to be here and hope we can help.  Osimertinib has better efficacy than gefitinib (including OS and reaching the brain)...

Hi Bob, Welcome to Grace.  I'm sorry about your sil.  Unfortunately, cancer becomes resistant to TKIs like tagrisso.  Sometimes all of the cancer becomes resistant at once and sometimes just parts...

Recent Comments

Hi Tammy,  Welome to Grace. …
By JanineT GRACE … on Tue, 05/16/2023 - 13:44
By Tndiuka10 on Fri, 05/12/2023 - 21:13
Hi Caregiver and welcome to…
By JanineT GRACE … on Fri, 05/12/2023 - 14:20
Hi Bob, Welcome to Grace.  I…
By JanineT GRACE … on Tue, 05/02/2023 - 12:29